Day: August 7, 2024

MALVERN, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) — Vishay Intertechnology, Inc., (NYSE: VSH), one of the world’s largest manufacturers of discrete semiconductors and passive electronic components, today announced results for the fiscal second quarter ended June 29, 2024. Highlights2Q 2024 revenues of $741.2 million Gross margin was 22.0% and included the negative impact of approximately 170 basis points related to the addition of Newport EPS of $0.17 2Q 2024 book-to-bill of 0.86 with book-to-bill of 0.82 for semiconductors and 0.90 for passive components Backlog at quarter end was 4.6 months“During the second quarter, we executed well on our Vishay 3.0 strategic plan, deepening our customer engagements supported by capacity that has landed and that we will continue to expand, and advancing our silicon carbide strategy as...

SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients Cash Balance of $459.7M as of June 30, 2024, Expected to Fund Operations into 2028 Ocular Will Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the second quarter ended June 30, 2024 and provided recent business highlights, including an update on the Phase 3 AXPAXLI™ (axitinib intravitreal...

Assets Under Management Now Approximately $1 Trillion $68 Billion of Capital Raised in the Quarter Annualized FRE and DE Grew 11% and 12% to $2.5 Billion and $2.4 Billion BROOKFIELD, NEWS, Aug. 07, 2024 (GLOBE NEWSWIRE) — Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) today announced financial results for the quarter ended June 30, 2024. Connor Teskey, President of Brookfield Asset Management stated, “We had another strong quarter, which included $68 billion of capital raised. There is strong momentum in our Credit business, providing solutions to our partners globally. We also continue to see unprecedented opportunities in our Renewable Power and Transition business, as evidenced by the recent partnership with Microsoft and our agreement to acquire Neoen, one of the world’s leading renewable power operators. With one of...

KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) — Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2024. “The second quarter financial results demonstrate the true earnings power of the Vertex business model,” stated David DeStefano, Vertex’s President, Chief Executive Officer and Chairperson of the Board. “We were GAAP earnings positive for the third quarter in a row, generated the highest level of quarterly cash provided by operating activities and free cash flow in our 46-year history and delivered our highest Adjusted EBITDA margin since we became a public company over four years ago.” DeStefano continued, “These are strong financial results, but we are just getting started. Several strategic...

Year-to-date consolidated earnings reflect strength of core utility operations Confirming consolidated earnings guidance of $2.36 to $2.56 per diluted share Continued investment in system improved reliability during recent heat waveSPOKANE, Wash., Aug. 07, 2024 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today announced financial results for the second quarter of 2024. Net income and earnings per diluted share for the second quarter and year-to-date 2024 compared to the same periods in 2023 are presented in the table below (dollars in thousands, except per-share data):   Second Quarter     Year-to-Date    2024     2023     2024     2023  Net Income (Loss) by Business Segment:                      Avista Utilities $ 23,935     $ 18,810     $ 91,443     $ 70,437  AEL&P   1,109       1,359       5,020       5,401  Other   (2,186 )     (2,685 )     (2,110 )     (3,509 )Total...

– Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors – STAMFORD, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the second quarter of 2024 and provided an update on recent company developments. “We are very pleased with the continued strong momentum of our U.S. launch of OGSIVEO for adults with desmoid tumors....

MORRISVILLE, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today reported financial results for the second quarter ended June 30, 2024. The company will host a webcast at 8:30 a.m. ET on August 7, 2024 to discuss the financial results and provide a corporate update. Dr. Roger Jeffs, Liquidia’s Chief Executive Officer, said: “We continue to face no legal impediments for the FDA approval of YUTREPIA for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and our commercial team stands ready to launch YUTREPIA contingent on the FDA’s final approval. If approved, we firmly believe that the ease of administration and...

Second Quarter 2024 Overview (all comparisons are made to the corresponding prior year second quarter unless otherwise specified):Net sales of $345.5 million decreased 1.3% from the record sales in the prior year. Implied orders increased 5.9% sequentially from the first quarter. Inventory initiatives drove $28.7 million sequential reduction from the first quarter. Diluted EPS of $(0.61), which included an $0.89 per share impact related to goodwill impairment, compared to $0.58; Adjusted EPS of $0.61 compared to $0.87. Backlog of $531.1 million as of June 30, 2024. Federal highway bill spending in the early stages of deployment, with only ~ 20% funds disbursed and 38% committed. Total state budgets are up 12% year-over-year in fiscal year 2024 following an 11% increase in fiscal year 2023.CHATTANOOGA, Tenn., Aug. 07, 2024 (GLOBE...